Indivior Pharmaceuticals, Inc. INDV 深 沪
已收盘 02-06 16:00:00 美东时间
34.36
-0.090
-0.26%
华盛通- 最 高35.45
- 今 开35.01
- 成交量 162.91万股
- 最 低 33.40
- 昨 收 34.45
- 总市值 42.96亿
- 52周最高 38.00
- 市盈率 静 2290.67
- 换手率 1.30%
- 52周最低 7.62
- 委 比 -13.04%
- 总股本 1.25亿
- 历史最高 38.00
- 量 比 1.08
- 振 幅 5.95%
- 历史最低 7.33
- 每 手 1
- 风险率 9.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, becoming a Delaware corporation. The former Indivior PLC is now Indivior Ltd., a wholly-owned subsidiary. Its shares are listed on Nasdaq under "INDV." The move aims to strengthen US market presence, enhance equity index inclusion, simplify governance, and bolster its position as a US-based innovation leader in treating opioid use disorder.
01-26 12:00
'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks
Kevin Mahn highlighted the potential impact of the recent tariff noise on the market and advised investors to look beyond the headlines.
01-21 17:54
Trump admin rolls back $2B in mental health, addiction grant cuts—report
The Trump administration is rolling back $2B in cuts to mental health and addiction programs, NPR reported, citing a Trump administration official. Letters restoring the funding are expected to be sen...
01-15 19:49
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
HC Wainwright & Co. Maintains Buy on Indivior, Raises Price Target to $48
HC Wainwright & Co. analyst Brandon Folkes maintains Indivior (NASDAQ:INDV) with a Buy and raises the price target from $35 to $48.
01-12 19:18
Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Indivior PLC announced its 2026 financial guidance with total net revenue expected between $1.125 billion and $1.195 billion, and SUBLOCADE® net revenue projected at $905 million to $945 million. Non-GAAP operating expenses are forecasted at $430 million to $450 million, while adjusted EBITDA is anticipated to range from $535 million to $575 million. The company has completed Phase I of its Indivior Action Agenda, focusing on growing SUBLOCADE re...
01-08 12:00
Indivior Announces Inclusion in the S&P SmallCap 600® Index
RICHMOND, Va., Dec. 22, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it will be added to the S&P SmallCap 600® index, effective tod...
2025-12-22 20:00
Indivior Says Data Published In 'JAMA Network Open' Shows SUBLOCADE 100mg And 300mg Improve Opioid Abstinence And Were Well-Tolerated With No New Safety Signals Identified
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified.Post-hoc analyses indicated the 300-mg monthly maintenance dose performed
2025-12-18 00:35
Indivior shares are trading higher after the company was added to the S&P SmallCap 600.
Indivior shares are trading higher after the company was added to the S&P S...
2025-12-08 22:09
Elastic, Veeva Systems, HIVE Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
2025-11-21 21:16
